Xencor, Inc. (XNCR) AI Stock Analysis
XNCR AI stock analysis summary
AI ResearchXencor, Inc. (XNCR) is a clinical-stage biopharmaceutical firm advancing engineered monoclonal antibody and cytokine therapeutics. The company generated $105.0M in trailing twelve-month revenue, remaining unprofitable with a net margin of -155.6%. However, it maintains strong balance sheet liquidity with $391.2M in net cash as of June 30, 2026.
- Market cap
- $1.70B
- Revenue (TTM)
- $105.0M
- P/E
- — fwd 68.0x
- 1Y return
- 52.8% S&P 500 16.8%
- Avg. target
- $31.42 37.5% vs last close
Bull case
- Xencor maintains a well-capitalized balance sheet with $391.2M in net cash and a current ratio of 6.39 as of June 30, 2026.
- Analyst sentiment is positive with 12 Buy or Strong Buy ratings and a mean price target of $31.42, implying 37.5% upside.
- The stock has generated strong momentum, rising 52.8% over the past year and trading 40.1% above its 200-day moving average.
Bear case
- The business generated free cash flow of -$138.3M in FY2025 and an EPS of -$2.16 over the trailing twelve months.
- Shares trade at elevated multiples, including a price-to-sales ratio of 16.2x versus the US-listed Healthcare peer median of 4.1x.
- Analyst estimates forecast revenue to decline 15.1% in the next fiscal year to $121.6M alongside an EPS of -$3.56.
What Xencor does
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat cancer and autoimmune diseases. Its portfolio includes commercial and licensed therapies such as Sotrovimab for SARS-CoV-2, Ultomiris for hematologic conditions, and Monjuvi for diffuse large B-cell lymphoma. Xencor is advancing several clinical candidates, including Plamotamab in Phase I trials for non-Hodgkin lymphoma, Vudalimab in Phase II trials for prostate cancer and solid tumors, and Tidutamab in Phase II trials for neuroendocrine tumors. The pipeline also includes XmAb306, XmAb104, XmAb564, and AMG 509.
Growth and profitability
Xencor delivered $125.6M in revenue in FY2025, up 13.7% from $110.5M in FY2024, but lower than $275.1M in FY2021. The five-year revenue CAGR from FY2020 to FY2025 stands at 0.5%. The company posted an operating margin of -141.4% and net income of -$91.9M in FY2025, supported by R&D expense of $239.4M. In the latest quarter ended June 30, 2026, quarterly revenue grew 17.5% year-over-year, while trailing twelve-month revenue was $105.0M with an operating margin of -72.4% and EPS of -$2.16.
Balance sheet and cash flow
As of June 30, 2026, Xencor held $456.5M in cash and short-term investments alongside $65.2M in total debt, yielding $391.2M in net cash. Total assets were $725.0M against shareholders' equity of $503.2M. The company has a current ratio of 6.39 and a debt-to-equity ratio of 0.13. Cash flow remains negative, with an operating cash flow of -$135.1M and free cash flow of -$138.3M in FY2025. Capital expenditures totaled $3.1M in FY2025, while the share count rose 25.7% over the past five years.
Valuation and performance
XNCR trades at a forward P/E of 68.0x, above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 16.2x compared to the peer median of 4.1x, and its EV-to-revenue ratio is 14.4x with an enterprise value of $1.52B. Over the past year, XNCR gained 52.8%, outperforming the S&P 500 (SPY) return of 16.8%. However, its 5-year return of -40.6% trailed the SPY return of 83.0%.
What analysts expect
Wall Street analysts hold 9 Strong Buy, 3 Buy, and 2 Hold ratings on XNCR, with no Sell or Strong Sell ratings. The mean price target of $31.42 represents a 37.5% upside from the last close of $22.85. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$3.15 on revenue of $143.2M. For next fiscal year, 12 analysts anticipate an EPS of -$3.56 on revenue of $121.6M. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.
Key risks and what to watch
- Short interest is elevated, with short percent of float standing at 31.2%.
- Dilution risk exists after a 25.7% increase in share count over the trailing five years.
- Substantial ongoing R&D spending, which reached $239.4M in FY2025, continues to drive operational losses.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this XNCR AI stock analysis
This page is an AI-written research summary of Xencor, Inc. (XNCR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: XNCR income statement, XNCR balance sheet, XNCR key metrics, XNCR analyst forecast, XNCR chart. See the XNCR stock overview for the latest quote and news.
XNCR AI stock analysis FAQ
Does Xencor pay a dividend?
No, Xencor does not pay a dividend. The company directs its capital toward research and clinical development.
What is Xencor's cash position?
As of June 30, 2026, Xencor had $456.5M in cash and short-term investments and $65.2M in total debt, resulting in net cash of $391.2M.
When does Xencor report earnings next?
Xencor's next earnings report is scheduled for November 4, 2026.
What is the consensus analyst price target for XNCR?
The mean analyst price target is $31.42, which is 37.5% above its closing price of $22.85 on October 16, 2026.